Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
about
Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapiesTargeting Endothelial Function to Treat Heart Failure with Preserved Ejection Fraction: The Promise of Exercise Training.Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.Prognostic significance of a multimarker strategy of biomarkers in acute heart failure.Right ventricular function in heart failure with preserved ejection fraction: a community-based studyMicroRNA signatures differentiate preserved from reduced ejection fraction heart failureGalectin-3 level and the severity of cardiac diastolic dysfunction using cellular and animal models and clinical indices.Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction.Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy.Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trialDiagnosing heart failure with preserved ejection fraction.Circulating biomarkers in patients with heart failure and preserved ejection fraction.Changes in cardiopulmonary reserve and peripheral arterial function concomitantly with subclinical inflammation and oxidative stress in patients with heart failure with preserved ejection fractionTargets for Heart Failure With Preserved Ejection Fraction.Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.Heart failure with preserved ejection fraction and skeletal muscle physiology.BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.Association between cardiac, renal, and hepatic biomarkers and outcomes in patients with acute heart failure.Evaluation of efficacy of metoprolol in patients having heart failure with preserved ejection fraction: A randomized, double-blind, placebo-controlled pilot trial.First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers.Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial.Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion.Pathophysiology of acute heart failure syndrome: a knowledge gap.Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction.Heart Failure With Preserved Ejection Fraction: A Perioperative Review.Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction.Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview.
P2860
Q27000263-D58B6303-5532-4B9B-BFFA-E960FDA068B2Q33863759-52CC992A-74EC-44DA-A60E-70032A9CB7FAQ34027687-17884887-9F2D-4802-82CB-7A19703DB8DCQ34479808-E03FC990-C50E-4B8F-BCFC-BD1FF7DC7626Q34772384-63E1EE5A-4120-4A44-A96F-67054E46E1DEQ35565357-5965AA08-21E5-415D-889F-1977AB6BEB33Q36297961-7055FA1C-65B5-470B-8856-555F4EBF586CQ36866650-529027C2-230B-43A7-9CB3-8776C2D3A270Q37058596-0D5456D4-B39C-4B90-9F6F-AFFB90BE1C78Q37328507-DFEB9146-7E3A-4C84-BB90-C7FE9E3543DCQ37408637-0A31BD28-F639-494A-99FB-93F2DD82076EQ37711521-F9E200C8-8686-4B24-95CF-D61BD5B7775CQ38127754-CC4C1635-8571-42D3-8CC1-6F354230C73DQ38152289-156A54B2-540C-4617-ACFB-F024E33F282EQ38285243-37C277B8-9DB5-4F32-BFF5-97729BD78966Q38688194-3657482D-4BB6-43BD-97F0-E9C56C71B46BQ38762394-2FF2F2AB-AB96-4674-9FD4-3867E4AC7C3EQ38931738-547D5F51-37C9-4C5A-BC50-3241E9AC8170Q38968210-42BDD09C-AE56-4713-AE77-62CECD117956Q39689820-11EF819D-7D9F-4983-8A36-28A98BF736AEQ41250771-0826D622-CADB-426B-B9A2-E3C916E355BFQ44339339-E24ED391-E860-46FF-90C2-09166AD95E3AQ46198550-020B24E8-222E-4660-8D3B-B08147038EF2Q47219894-59ABCB99-FE36-4337-A0F4-EA3076622AD8Q48095229-038E7458-CC14-4728-961E-2970E06AC95CQ48725493-BF9FC531-1CD5-4CF6-A169-2FB373A0AA51Q50226285-D1FB7CC0-E20C-4689-B82A-21A794BC2B30Q55499529-CB98734A-1524-4276-9908-07A9BF9548F4Q55610979-A7A61E4D-DA82-427D-9FEF-1D50219332DA
P2860
Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 October 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers in acutely decompen ...... or reduced ejection fraction.
@en
Biomarkers in acutely decompen ...... or reduced ejection fraction.
@nl
type
label
Biomarkers in acutely decompen ...... or reduced ejection fraction.
@en
Biomarkers in acutely decompen ...... or reduced ejection fraction.
@nl
prefLabel
Biomarkers in acutely decompen ...... or reduced ejection fraction.
@en
Biomarkers in acutely decompen ...... or reduced ejection fraction.
@nl
P2093
P2860
P1476
Biomarkers in acutely decompen ...... or reduced ejection fraction.
@en
P2093
Anita Deswal
Barry A Borlaug
Gregory D Lewis
Horng H Chen
Kalkidan Bishu
Marc J Semigran
Margaret M Redfield
Martin M LeWinter
Steven McNulty
P2860
P304
763-770.e3
P356
10.1016/J.AHJ.2012.08.014
P407
P577
2012-10-16T00:00:00Z